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Abstract: Glycan parts of glycoconjugates on the surfaces of cells regulate many kinds of interactions between the cells and their immediate
environments. Alterations in glycosylation on the cancer-associated glycoproteins are responsible for changes in their molecular
interactions and biological functions. Glycosylation changes occur in the core and/or at the nonreducing end of the oligosaccharide
chains of N-glycans. In this review, we focus on the branching of the common core structure of N-glycans, the responsible enzyme,
and the extensions of some of the branches causing size increases on the surface of tumor cells. Abnormal branching, elongation of the
branches, and increasing size of the common core of N-glycans are the typical features of these changes and are related with malignant
transformations. Seven N-acetylglucosaminyltransferases (GnTs) (GnT-I, GnT-II, GnT-III, GnT-IV, GnT-V, GnT-VI, and GnT-IX) and
α1,6-fucosyltransferase (FUT8) initiate the new branches on the core. GnT-IV, GnT-V, and GnT-IX initiate the branches available for
poly-LacNAc extensions, which are responsible for tumor progression and metastasis. GnT-III prevents the catalytic activity of GnT-II,
GnT-IV, GnT-V, and FUT8 to form branching and elongation of the branches. The contributions of GnT-III and the other enzymes to the
cancer progression are in conflict with each other. While GnT-III prevents cancer, the others increase metastasis. The function of FUT8
is related to signal transduction and its activity is higher in tumor tissue than in healthy tissue. The impact of glycosylation changes on
some of the cancer-associated proteins (growth factor receptors, adhesion and signal molecules, CD147, TIMP-1, and matriptase) is
also summarized.
Key words: N-Glycan core branching, glucosyltransferases, FUT8, poly-LacNAc, galectin-3, adhesion and signal molecules, growth
factor receptors, CD147, TIMP-1, matriptase

1. Introduction
In a 2009 special issue of Biochimica et Biophysica Acta
dedicated to Dr Eric Berger, a colleague explained how
his interest in glycosylation defects in human diseases
began and how Berger, a medical doctor, had become a
glycobiologist with the identification of the first disease
caused by a glycosylation disorder in 1978 (Hennet,
2009). In the following years, the description of many
human diseases related to glycosylation defects gradually
increased. Altered N-glycosylation patterns of proteins
have been described with increasing age and in several
diseases including cancer (Ruhaak et al., 2011).
The cell surface cover, the glycocalyx, is composed
of glycan chains (oligosaccharides or polysaccharides),
parts of glycoconjugates found within the structure
of the plasma membrane and the extracellular matrix
(ECM). Glycoconjugates are hybrid molecules including
glycoproteins, proteoglycans, glycosphingolipids, and
glycophosphatidyl inositol anchors (Figure 1). Light and
* Correspondence: sabire.karacali@ege.edu.tr
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heavily glycosylated plasma membrane glycoproteins have
different functions. They are the molecules indicating
differentiation (Feizi, 1981, 1985, 1987, 1991), blood
groups in ABO and Rh systems (Eyers et al., 1994;
Fredriksson et al., 2010), normal and cancer stem cells
(Yin et al., 1997; Irollo and Pirozzi, 2013), and tumorassociated antigens (Huang et al., 2013; Saldova et
al., 2013b). Membrane receptors for growth factors
(Matsumoto et al., 2008; Wu et al., 2013; Tan et al., 2014)
and for Delta/Serrata (Takeuchi and Haltiwanger, 2014)
bear glycans affecting the sensitivity of the cells to their
molecular targets. Membrane transporters such as Na+-KATPase (Tokhtaeva et al., 2010), the ATP-binding cassette
(Hollenstein et al., 2007), glucose transporters (Haga
et al., 2011), and transmembrane glycoproteins such as
cadherin and integrin, playing an important role in cell
adhesion and signaling (Zhao et al., 2008; Bassagañas et
al., 2014), and a transmembrane serine protease involved
in epithelial homeostasis in both health and disease
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Figure 1. Cell surface glycoconjugates, modified from Varki et al. (2009) with permission.

situations (Gray et al., 2014) are all glycoproteins. Glycan
parts of the cell-surface glycoconjugates have a function
in self- and nonself-discrimination (Karaçalı et al., 2000;
Bayro and Deveci, 2006; Eratak and Karaçalı, 2006; Özkan
and Karaçalı, 2006). The glycan structures also decorate
signal and carrier molecules in serum. Follicle-stimulating
hormone (Lombardi et al., 2013), luteinizing hormone
(Mi et al., 2014), sex hormone-binding globulin (SumerBayraktar et al., 2012), and coagulant Factor VIII (Canis et
al., 2012) are some such examples.
The cell-surface glycoproteins are responsible for many
kinds of interactions between cells and their immediate
environments. Free or membrane-associated glycanbinding proteins (lectins, galectins, siglecs, and mannosebinding free and membrane-attached receptors) play
critical roles in these interactions. Events mediated by these
interactions are recognition, antirecognition, adhesion,
signal transduction, endocytosis, vesicle releasing, and
migration between the organelles and the cells, on both
molecular and cellular levels. Characteristic surface
glycosylation patterns, glycotypes, providing a molecular
signature, serve to discriminate the differentiated cells
from each other.

Glycosylation changes affecting the disruption of
normal cellular interactions play an important role in
determining cell fate during embryonic and pathological
development (Karaçalı, 2003; Varki et al., 2009; Dodla et al.,
2012; Nairn et al., 2012). The alterations occurring on the
glycans of cell-surface glycoconjugates, such as signaling
and attaching and anchoring molecules, receptors, ligands,
enzymes, differentiation and cancer-associated antigens,
antibodies, and membrane transporters, dramatically
change the normal cellular interactions between cells
and their microenvironments. A significant relationship
between the alteration of cell-surface glycan profiles and
cancer progress has been described (Borzym-Kluczyk et
al., 2012; Saldova et al., 2013a; Zhang et al., 2014). The
modifications of cell-surface glycosylation are responsible
for the behavioral changes of tumor cells, including
invasion and metastasis (Li et al., 2010; Kang et al., 2011;
Taniguchi and Korekane, 2011; Tian and Zhang, 2013;
Zhang et al., 2013; Christiansen et al., 2014; Häuselmann
and Borsig, 2014).
During the last few years, glycosylation abnormalities
in genetic diseases have been highlighted as ‘congenital
disorders of glycosylation’ (Cylwik et al., 2013a, 2013b;
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Jaeken, 2013; Rosnoblet et al., 2013). Distribution of
significant glycan structures on tumor cells makes the
carbohydrates attractive targets as cancer biomarkers
(Meany and Chan, 2011; Tuccillo et al., 2014) for the new
and much publicized objective of personalized therapy
(Contessa et al., 2008; Padler-Karavani, 2014) as well as for
the development of anticancer vaccines (Hakomori, 2001;
Li et al., 2010) and drugs (Kok and Sietsma, 2004; GerberLemaire and Juillerat-Jeanneret, 2010).
Alterations in glycosylation occur in different parts (core
and/or antennae) of glycan structures of glycoconjugates
of tumor cells, and in various forms (Brooks et al., 2002;
Varki et al., 2009; Karaçalı et al., 2011). In general, an
increased number of branches on the core structures and
their extensions by addition of new monosaccharides cause
the formation of heavily glycosylated glycoconjugates. The
addition of new epitopes on proximal and distal parts of
oligosaccharide chains and the alterations in linkage types
at terminal monosaccharides alter the adhesive interactions
of the cells. These alterations occur on the glycans of
N-linked glycoproteins, O-linked glycoproteins (mucins
and proteoglycans), and glycosphingolipids. In this review
we focus particularly on the branching and elongation
of oligosaccharide chains occurring in the common core

structure of N-glycans on cell-surface glycoconjugates in
cancer cells. These changes are responsible for the increase
in size and the occurrence of metastatic phenotypes.
Responsible enzymes and their key targets associated with
cancer are also addressed.
2. Alterations on the common core of N-glycans
2.1. Branching on the common core structure
Dolichol-linked precursors, common precursors of
N-glycans consisting of 14 glycan units (2GlcNAc, 9Man,
3Glc), are formed at the initial synthesis stage of all N-linked
glycoproteins (Brooks et al., 2002; Varki et al., 2009; Taylor
and Drickamer, 2011). First the N-acetylglucosamine
(GlcNAc) sugar of the precursor is attached to the amide
nitrogen of the asparagine residue in the β-glucosidic
linkage (GlcNAcβ1-Asn) by the oligosaccharyltransferase.
After transferring the precursor to the growing peptide,
maturation reactions of the glycans start in the lumen of
the rough endoplasmic reticulum and continue in Golgi
compartments. Glycosidases and glycosyltransferases
successively modify the structure of the precursor. The
differential actions of these enzymes cause the formation
of high-mannose and hybrid and complex types of
N-linked oligosaccharides (Figure 2). All of these types

Figure 2. The precursor and the basic types of N-glycans. The common core structure is shaded.
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have a common core structure consisting of 3 mannose
(Man) residues and 2 GlcNAc residues.
Appropriate variations occurring on the glycans
direct the protein folding, sorting, correct targeting, halflife, and a number of molecular interactions (adhesion,
receptor-ligand binding, and activation) of glycoproteins.
Characteristic combinations of these glycan types appear
on the surfaces of each differentiated cell. Differentiated
healthy cells, together with a few 3- and 4-branched
glycans, contain most abundantly 2-branched complex
structures on their N-glycoproteins.
In tumor cells, increased branching on the core
of N-glycans is a typical feature, except for truncated
expression of oligosaccharides (Brooks et al., 2002; Varki et
al., 2009). Two Man residues are attached to the first Man
residue by 2 different linkages (α1-6 and α1-3), forming
the initiation of 2 basic arms on the core structure. Specific
N-acetylglucosaminyltransferases (GlcNAc-Ts, GnTs)
catalyze the transfer of GlcNAc sugar from the active donor,
UDP-GlcNAc, to specific positions on the core mannoses
of N-glycans via a specific glycosidic linkage. Three, 4, and
more branches can be started by the activity of a particular
GnT on the core structure (Chen et al., 2009). Each of the
attached GlcNAc sugars provides a new substrate for the
succeeding glycosylation and their number determines the
number of branches or antennaries originating from the
common core structure on hybrid and complex N-glycans.
The enzymes catalyzing glycosidic linkages at the starting
points of the new branches are seen in Figure 3.
The enzymes responsible for the addition of the
new branches and for the increase in core size are well
characterized by several GnTs and a fucosyltransferase
(FUT8). In vertebrates, 7 different GnTs (productions of
Mgat genes), indicated as GnT-I, -II, -III, -IV, -V, -VI, and
-IX (Figure 3), have been determined to be involved in the
initiation of the branching of the complex N-glycan core
structure (Taniguchi and Korekane, 2011; Takamatsu et
al., 2013).
Galactosyltransferases and sialyltransferases are the
other important enzymes. One (Taylor and Drickamer,
2011) or more (Antonopoulos et al., 2012) branches are
extended by the addition of galactose and GlcNAc residues,
which produce the polylactosamine (poly-LacNAc)
extensions. Correlations between the originating branches
of poly-LacNAcs and regulation of tumor development,
invasion, metastasis, aggressiveness, and survival have
been investigated (Seto et al., 2013). Sialic acid attached
like a cap at the nonreducing end of the oligosaccharide
chains prevents further elongation of the chains.
2.1.1. N-Acetylglucosaminyltransferases (GlcNAcTs, GnTs)
Sequential activity rules for the GnTs that initiate the
branching of the complex N-glycan core structure were
established by Brockhausen et al. (1988). GnT-I and GnT-

II are involved in initiating the synthesis of the various
branches of complex N-glycans.
GnT-I, encoded by the Mgat1 gene (Kumar and
Stanley, 1989), acts before all the other GnTs. GnT-I is
required for the conversion from the high-mannose type
(with 5 Man residues) to the hybrid and complex types
(with 3 Man residues) of N-glycans (Yip et al., 1997; Chen
et al., 2002; Taniguchi and Korekane, 2011). It catalyzes the
formation of β1-2 linkage by transferring a GlcNAc sugar
to the Man residue on the α1-3 arm of the core structure
with 5 mannoses (Figure 4). Two Man residues on the α1-6
arm are removed by catalytic activity of α-mannosidase II.
This structure is the substrate for the GnT-II and GnT-III
enzymes. Mutation on the corresponding gene, Mgat1,
causes embryonic lethality (Loffe and Stanley, 1994;
D’Agostaro et al., 1995).
GnT-II controls the conversion of hybrid type to
complex type structures (D’Agostaro et al., 1995; Ye and
Marth, 2004). GnT-II recognizes the structure formed by
the catalytic activity of α-mannosidase II and catalyzes the
β1-2 glycosidic linkage by adding a GlcNAc to the α1-6
arm on the core; a 2-branched core structure is formed
(Figure 4). Activity of GnT-II is prerequisite (Zhang et
al., 2000) for the GnT-IV, GnT-V, and GnT-IX activities
that are responsible for cancer progression. Mutation
on corresponding gene Mgat2 causes a number of
abnormalities in early stages of development (Wang et al.,
2001).
GnT-III (the corresponding gene is Mgat3) catalyzes
the formation of β1-4 glycosidic linkage by transferring
a bisecting GlcNAc to the first Man residue on the core
(Figures 3 and 4). The bisecting GlcNAc is found in
various hybrid and complex N-glycans. The presence of
a bisecting GlcNAc prevents subsequent processing and
elongation of N-glycans, inhibiting the catalytic activity of
the GnT-II, GnT-IV, GnT-V, and FUT8 enzymes that are
responsible for branching of the core structure in vitro
(Brockhausen et al., 1988; Isaji et al., 2010; Taniguchi
and Korekane, 2011; Miwa et al., 2012; Xu et al., 2012).
However, a contrary suggestion is also present. The
glycomic profiles of several N-glycans having a bisecting
GlcNAc revealed that they carry lactosamine (LacNAc)
repeats and also a core fucose (Fuc) sugar (North et al.,
2010). The presence of the bisecting GlcNAc on the cell
surface glycoproteins, such as E-cadherin and integrins,
probably alters N-glycan conformation, which affects their
interaction with carbohydrate-binding proteins, such as
galectins and siglecs. The bisecting GlcNAc of N-glycans
on adhesion and signal molecules regulates cellular
signaling and tumor progression by modulating N-glycan/
galectin interactions (Miwa et al., 2012)
Overexpression of GnT-III increases the bisected
N-glycans but reduces the β1-6 GlcNAc branching
structures on target glycoproteins. Knockdown of
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Figure 3. The branches on the common core structure of N-glycans. The glycosyltransferases that
initiate formation of the branches and the known branches that bear poly-LacNAcs, and related
enzymes, are indicated. Modified from Taniguchi and Korekane (2011) with permission.

endogenous GnT-III expression results in increased cell
migration (Taniguchi and Korekane, 2011). As a result, the
enzyme suppresses the integrin-mediated cell motility and
has an inhibitory effect on cancer metastasis (Kariya et al.,
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2010; Taniguchi and Korekane, 2011; Xu et al., 2012). The
Mgat3 gene has a tissue-specific expression pattern. High
expression levels appear particularly in mouse brain and
kidney (Miwa et al., 2012)
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Figure 4. Branching on the common core structure of N-glycans. Sequential activities of responsible GnTs. Modified from Taniguchi
and Korekane (2011) with permission.

GnT-IV (the corresponding gene is Mgat4) catalyzes
the formation of β1-4 glycosidic linkage by transferring a
GlcNAc sugar to the α1-3 Man arm of the N-glycan core.
The enzyme acts on biantennary complex-type N-glycan
and forms the 3-antennary core structure (Figures 3
and 4). The third branch extends by addition of LacNAc
repeats, poly-LacNAcs that bear galectin-binding epitopes
(Takamatsu et al., 2010, 2013; Taniguchi and Korekane,
2011). Secreted galectins are bound to β-galactoside
sugar on poly-LacNAcs and cross-link glycoconjugates
on the cell surface and in the ECM by producing a lattice
formation. The galectin-glycoprotein lattice structure
controls glycoprotein activity.
GnT-IV has 2 isoenzymes, GnT-IVa and GnT-IVb, and
they both contribute to the galectin-mediated glycoprotein
clustering on the cell surface (Takamatsu et al., 2013). In
humans, GnT-IV isoenzymes have the same specificities
but different affinities for sugar donors and acceptors.
GnT-IVa has higher affinities and is more active than GnTIVb (Oguri et al., 2006). The results obtained from GnTIVb-deficient and both GnT-IVa- and GnT-IVb-deficient
mice showed that GnT-IVb is expressed in various
organs, whereas GnT-IVa expression is restricted to the
gastrointestinal tissues (Takamatsu et al., 2010). GnT-IVa
is expressed in malignant and premalignant trophoblastic
cells but not in normal or benign cells (Niimi et al., 2012).
On the contrary, in pancreatic cancer, the increased
expression of GnT-IVb was found in tumor tissue, whereas
GnT-IVa expression was found in surrounding normal
tissues (Ide et al., 2006).
β1-Integrin and a cancer-associated antigen,
extracellular matrix metalloproteinase (MMP) inducer
CD147, are the target proteins of the enzyme GnT-

IVa. Overexpression of GnT-IVa causes an increase in
branching of complex N-glycans on CD147, leading
to enhanced cell migration and metastatic capabilities.
However, downregulation of GnT-IVa reduces the
branching and decreases cell migration and metastasis
(Fan et al., 2012). In GnT-IVb-deficient mice, total
enzymatic activity is preserved at a level comparable to the
wild type due to upregulated Mgat4a expression (Niimi et
al., 2012). Transcription factor Ets-1 is responsible for this
compensation. Ets-1 evolves from GnT-IVb deficiency and
induces the expression of GnT-IVa and GnT-V enzymes
(Niimi et al., 2012).
GnT-V (the corresponding gene is Mgat5) is an
enzyme that has dual functions as a membrane-bound
glycosyltransferase and a soluble angiogenic factor (Saito
et al., 2002; Nakahara et al., 2006). The membrane-bound
form of GnT-V catalyzes the formation of β1-6 linkage
by transferring a GlcNAc sugar to the α1-6 arm of the
N-glycan core (Figures 3 and 4). This added GlcNAc residue
provides an initial substrate to form the poly-LacNAc
extension. Expression of poly-LacNAcs on the N-glycan
core, which is often modified with Fuc and sulfate residues
(Mitsui et al., 2012) on the surfaces of many cancer cells,
indicates their association with cellular differentiation and
oncogenesis (Hua et al., 2012; Gao et al., 2014).
A close relationship between the metastatic potential
of tumor cells and formation of poly-LacNAc extensions
has been reported (Chakraborty and Pawelek, 2003; Pinho
et al., 2013; Pocheć et al., 2013; Seto et al., 2013; Tanaka et
al., 2013). The degree of the invasiveness and metastatic
potential appears related to the amounts of poly-LacNAc
chains. Comparison of the common glycoproteins from
primary and metastatic melanoma cell lines shows that
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the metastatic melanoma cells bear larger amounts of
poly-LacNAc chains than the primary cells (Kinoshita et
al., 2014). Observation of an inhibition in invasion and
metastasis events following downregulation of GnT-V in
BGC 829 cells (Huang et al., 2014) supports that suggestion.
There are several supporting reports indicating that the
gene of GnT-V, Mgat5, is correlated with metastasis. Tumor
growth and metastasis were suppressed by knockout of
Mgat5 in animal studies (Demetriou et al., 1995; Yao et al.,
1999; Granovsky et al., 2000; Yamamoto et al., 2000; Ihara
et al., 2002; Saito et al., 2002; Tsui et al., 2008).
GnT-IX was recently designated (Inamori et al., 2003)
as GnT-Vb (Kaneko et al., 2003) enzyme forming a β1-6
branched structure (Figures 3 and 4) on the α1-3 arm of
the N-glycan core (Taniguchi and Korekane, 2011). In the
brain, GnT-IX catalyzes the branched form of O-mannosyl
glycan structures, as well (Kanekiyo et al., 2013). Brainspecific gene expression of this enzyme is regulated by
epigenetic histone modification (Kizuka et al., 2011, 2014;
Korekane et al., 2013).
2.1.2. α1,6-Fucosyltransferase (FUT8)
FUT8 (α1,6-fucosyltransferase) catalyzes the transfer of
a Fuc sugar from the active sugar donor, GDP-fucose, to
the first GlcNac residue linked to the asparagine residue
of hybrid and complex N-glycan cores. FUT8 activity
and increased core fucosylation play an important role
in cancer development (Bernardi et al., 2013). In general,
FUT8 activity is higher in tumor tissue than in healthy
tissue and is related to sex, type of growth, and tumor stage
(Muinelo-Romay et al., 2008). Overexpressed FUT8 and
increased core fucose were observed in several malignant
human cancers, such as in the serum of prostate (Saldova
et al., 2011) and ovarian (Saldova et al., 2013a) cancer
cells in cell lines of nonsmall cell lung cancer (Chen et al.,
2013), and in tissues of colorectal (Muinelo-Romay et al.,
2008) and hepatocellular (Li et al., 2013; Yin et al., 2014)
carcinomas. However, increased levels of tetraantennary
glycan without core fucosylation were also observed in
hepatocellular carcinoma (Mehta et al., 2012).
Knockdown FUT8 in aggressive lung cancer cell
lines significantly inhibits their malignant behaviors
(Chen et al., 2013). In contrast, the level of FUT8 protein
was decreased in gastric tumor tissues compared to the
adjacent nontumor tissues (Zhao et al., 2014). Decreased
core fucosylation in both tissue and serum from gastric
cancer patients may result from the decreased expression
of FUT8 (Liu et al., 2013). The results of glycoproteomic
and microarray analyses show that core fucose regulates
the function of proteins associated with malignancy. Cellsurface antigens, antibodies, receptors, sugar transporters
on Golgi membranes, and adhesion molecules (E-cadherin
and integrins) are modified by FUT8 (Chen et al., 2013).
Core fucosylation of several growth factors has been
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demonstrated to be required for signal transduction and
alters the sensitivity for ligands. Core fucosylation of
N-glycans of epidermal growth factor receptor (EGFR) is
necessary for the binding of epidermal growth factor (EGF)
(Wang et al., 2006). FUT8 promotes EGFR dimerization
and phosphorylation (Liu et al., 2011) as well as cellular
growth (Matsumoto et al., 2008). Knockdown FUT8 leads
to a decrease in the growth response. Decreased core
fucosylation of EGFR causes a reduced activation of EGFinduced phosphorylation of the EGFR in gastric cancer
(Zhao et al., 2014). Core fucose is required for the ligand
binding affinity and function of TGF-β1 receptor (Wang et
al., 2005; Venkatachalam and Weinberg, 2013).
Adhesion molecules, E-cadherin and integrins, play
an important role in cancer development and progression.
FUT8 regulates E-cadherin-mediated cell adhesion and
is expressed in metastatic lung cancer cell (Geng et al.,
2004). The increase of core fucosylation of E-cadherin
leads to strengthened cell–cell adhesion (Osumi et al.,
2009). Core fucosylation is essential for integrin-mediated
cell migration and signal transduction (Zhao et al., 2008).
FUT8 plays an important role in embryonic development;
70% of FUT8-deficient [FUT8 (-/-)] mice that lack the core
fucose structure die within 3 days after birth. The others
may survive for several weeks, but they show growth
retardation. In embryonic fibroblasts from FUT8 (-/-)
mice, the levels of bisecting GlcNAc on β1-integrin and
N-cadherin were increased. The responsible enzyme, GnTIII, that inhibits cell migration in metastasis is regulated by
FUT8 deficiency in vivo (Kurimoto et al., 2014).
All these alterations, with the increase in size and
structural complexity of the N-glycan core, cause
functional changes of the glycans on the surface cover of
the cells. In general, the degree of branching is very closely
related to tumorigenesis. The increase in N-glycan core
branching and the formation of long linear or branched
poly-LacNAcs cause tumor progression. Reduced N-glycan
branching degree retards tumor progression (Mehta et
al., 2012). Briefly, GnT-I and GnT-II are prerequisites in
the biosynthesis of highly branched N-glycans. GnT-III
prevents cancer of the cells. GnT-IV, GnT-V, GnT-IX,
and FUT8 are responsible for tumor progression and
metastasis.
2.2. Elongation of the oligosaccharide chains, polyLacNAcs, and galectin-3
Carbohydrate chains on all types of glycoconjugates carry
the repeats of N-acetyllactosamine (Gal-GlcNAc, LacNAc),
poly-LacNAc extensions. Branching and composition
of N-glycan cores affect the extent of poly-LacNAc
chains. They are found more often in tetraantennary and
triantennary N-glycans. The branch with β1-6 glycosidic
linkage catalyzed by GnT-V on the α1-6 arm and 2 branches
catalyzed by GnT-IX (GnT-Vb, isoenzyme of GnT-V) and
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by GnT-IV on the α1-3 arm are available to carry polyLacNAc chains (Figure 3). According to the prevalent
hypothesis, the poly-LacNAc extension is attached to one
of the specific branches on the common trimannosyl core
structure. However, the poly-LacNAc chains were equally
distributed on all branches and not selectively enriched
on a specific N-glycan branch in activated cytotoxic T
lymphocytes after antigenic stimulation (Antonopoulos et
al., 2012). Two kinds of poly-LacNAc chains are known,
indicated as type I and type II according to linkage types.
Type II is the most common chain form and the linkages
are Galβ1-4GlcNAc and GlcNAcβ1-3Gal in LacNac
repeats. In type I, the linkages are Galβ1-3GlcNAc and
GlcNAcβ1-4Gal in LacNAc repeats.
Linear and branched poly-LacNAcs form i-histo and
I-blood group antigens, respectively (Twu et al., 2010)
(Figure 5). These are present on the surfaces of red blood
cells and other somatic cells. Poly-LacNAc structures are
important ligands for galectin-mediated cell adhesion to
ECM proteins, such as laminin and fibronectin (Sauerzapfe
et al., 2009). Extended and branched poly-LacNAcs cause
the formation of multiantennary complex type N-glycans
of enormous size. The enzyme required for branching is
β1-6 branching glycosyltransferase (IGnT-V, GCNT2).
Correlations between the originating branches of polyLacNAc and regulation of tumor development, invasion,
metastasis, aggressiveness, and survival have been
investigated (Seto et al., 2013). The increase in branching
and in extension of poly-LacNAc is associated with tumor
cell metastasis (Nabi and Dennis, 1998; Ishida et al.,
2005; Hua et al., 2012; Peng et al., 2012; Liu et al., 2014).
In contrast, reduced degrees of branching and extension
of poly-LacNAc chains retard tumor progression and
metastasis (Togayachi et al., 2010; Liu et al., 2011, 2014;
Shen et al., 2011).
Required enzymes for the formation of poly-LacNAc
are β1,4-galactosyltransferases (β4GalT) and β1,3-Nacetylglucosaminyltransferase (β3GnT). The length of
poly-LacNAc extensions changes depending on the

repeating action of these 2 transferases (Nabi and Dennis,
1998). β4GalT is present in a unique form in all cells.
However, the number of known β3GnT genes is 8 in
mice and they are expressed in a tissue-specific manner
(Henion and Schwarting, 2014). Each of the 8 determined
β3Gn-Ts enzymes (Seko and Yamashita, 2005; Peng et
al., 2012; Henion and Schwarting, 2014) synthesizes a
different glycan type. β3Gn-T8 (homolog to β3Gn-T2)
(Togayachi et al., 2010) has a central role in carcinogenesis
and catalyzes the formation of poly-LacNAc on β1-6
branches of N-glycans (Hoja-Łukowicz et al., 2013; Liu et
al., 2014; Ni et al., 2014). β3Gn-T2 regulates the expression
of extended poly-LacNAc chains that are essential for
axon guidance and neuronal survival in the olfactory
epithelium (Henion and Schwarting, 2014). β3Gn-T8 and
β3Gn-T2 have the same specificity to act efficiently on
tetraantennary and triantennary N-glycan cores (Seko and
Yamashita, 2005). The mixing of β3Gn-T8 and β3Gn-T2
in vitro forms a heterocomplex and its enzymatic activity
is greatly enhanced compared to the individual enzymes
(Seko and Yamashita, 2005).
The branched and extended structure of poly-LacNAc
chains is responsible for lattice formation with galectins.
The galectin-glycoprotein lattice structure controls the
activity of glycoproteins at the cell surface by regulation
of their membrane localization, lateral mobility, and
clustering. The lattice formation inhibits endocytosis
(Grigorian et al., 2009), which is important for receptor
turnover. Galectin-glycoprotein lattices can regulate the
duration of signaling and receptor turnover. Thus, they
can control the decision between cell growth and arrest
(Rabinovich et al., 2007). Long poly-LacNAc chains with
additional sialyl Lewisx epitopes are highly metastatic,
while short poly-LacNAc chains with many more sialyl
Lewisx epitopes are not metastatic (Srinivasan et al., 2009).
This is probably related to the presence of the lattice
formation for poly-LacNAc chains of different lengths.
A chemotherapeutic agent, 5-FU, inhibits the
expression of β3Gn-T8, and this causes a reduction of poly-

Figure 5. i and I antigens on poly-LacNAc chains. Galectin-3 recognizes proximal LacNAc units.
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LacNAc on CD147 in colon cancer cells (Gao et al., 2014).
The levels of β3Gn-T8 and poly-LacNAc chains gradually
increase from low to high metastatic potential in colorectal
cancer cell lines. A positive correlation between β3Gn-T8
expression and highly glycosylated CD147 indicates that
β3Gn-T8 plays a critical role in the metastasis of colorectal
cancer (Lu et al., 2014; Ni et al., 2014).
Galectins are soluble proteins recognizing and binding
β-galactosides on poly-LacNAc extensions of the N-glycan
core. They are found in the nucleus, cytoplasm, cell
surface, and ECM, as well as in biological fluids (Argüeso
and Panjwani, 2011). Different galectins have different
specificities for oligosaccharides. Galectin-3 (Gal-3) binds
proximal LacNac repeats on the poly-LacNAc chains of
N-glycan cores (Stowell et al., 2008). Gal-3, existing as a
monomer in solution, produces a pentameric structure
through self-associated intermolecular interactions
and mediates crosslinking of proteins, forming a lattice
organization (Chiu et al., 2010; Argüeso and Panjwani,
2011). Galectin-glycan lattices create homotypic or
glycoprotein complexes that are involved in cellular
signaling related to a variety of cell functions, including
cell adhesion, migration, invasion, angiogenesis, immune
functions, apoptosis, and endocytosis (Garner and Baum,
2008; Nangia-Makker et al., 2008; Chiu et al., 2010; Çay,
2012). During the ECM remodeling, new Gal-3-glycan
lattices occur and mediate new interactions (Lagana et al.,
2006; Reticker-Flynn et al., 2012; Priglinger et al., 2013).
Galectin-glycoprotein lattices control the organization
of plasma membrane domains like lipid rafts and the
direction of targeted delivery of glycoproteins to the cell
surface. They determine the duration of signaling by
inhibiting the endocytosis of glycoprotein receptors (such
as growth factors) from the cell surface (Garner and Baum,
2008).
The GnT-V expression-dependent Gal-3-TGFβR
lattice preserves growth factor receptor densities at the
level necessary for invasive phenotypes in transformed cell
surfaces (Rabinovich et al., 2007). GnT-IVa expressiondependent lattice formation increases the cell-surface halflife of glucose transporter 2 on pancreatic β-cells, probably
by inhibiting receptor endocytosis (Ohtsubo et al., 2005;
Rabinovich et al., 2007). These points indicate that lattice
structures are involved in cellular signaling in various
ways depending on the origin of the poly-LacNAc chains.
3. Changes in cancer-associated proteins
It appears that the enzymes (GnT-IV, GnT-V, and GnTIX) initiating branches that possess poly-LacNAc chains
on the core of N-glycans affect the same proteins involved
in cancer development. GnT-V has a number of target
proteins involved in tumor progression. Well-defined
substrate proteins of GnT-V are growth factor receptors
(such as EGF and TGF-β), adhesion and signaling
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molecules (cadherin and integrins), tumor-associated
antigen (CD147), tissue inhibitor of metalloproteinase-1
(TIMP-1), membrane-bound serine protease (Matriptase),
and lysosomal-associated membrane proteins 1 and 2
(Lamp-1 and Lamp-2). Each one contributes in a distinct
manner to tumor progression and metastasis (Ochwat et
al., 2004; Siddiqui et al., 2005; Kim et al., 2008; Taniguchi
and Korekane, 2011; Drake et al., 2012; Christiansen et
al., 2014). Expression of β1-6 GlcNAc branching on these
substrate glycoproteins is related to a variety of tumors in
malignant transformation (Ihara et al., 2002). Depending
on the structural changes of N-glycans in these target
proteins, different implications of GnT-V have been
reported in cancer metastasis.
The occurrence of poly-LacNAc chains is very
important for tumor progression and metastasis. The
branched structure catalyzed by GnT-V on several
glycoproteins has received particular attention in the
literature. GnT enzymes have different affinities for the
same common core substrate. This produces a restriction
mechanism among the GnTs. For example, GnT-I and
GnT-II have nearly 250- and 20-fold higher affinity for
UDP-GlcNAc than GnT-V, respectively (Chen et al., 2009).
Higher expression of GnT-I reduces GlcNAc branching on
the core of N-glycans by reducing the availability of UDPGlcNAc to GnT-IV and GnT-V.
3.1. Growth factor receptors
Growth factor receptors (GFRs) are synthesized in the
cytoplasm and then transported toward the plasma
membrane within the vesicles originating from Golgi
membranes (Luo et al., 2013; Katsuda et al., 2014). It has
been suggested that N-linked glycosylation is required for
the successful cell-surface transportation and sensitivity of
the TGF-β receptor in gastric carcinoma cell lines (Kim et
al., 2012). N-glycans on GFRs such as EGF, TGF-β, IGF, and
PDGF are modified by overexpression of GnT-V and high
affinity ligands, poly-LacNAcs, for galectins are generated
on tumor cells (Lajoie et al., 2007). The increase of β1-6
branches bearing poly-LacNAcs has an influence on ligand
binding, dimerization, and promotion of function of
EGFRs (Guo et al., 2004; Takahashi et al., 2004).
The formation of the lattice between increased polyLacNAc chains and Gal-3 causes the inhibition of receptor
endocytosis (Partridge et al., 2004; Häuselman and Borsig,
2014), the prolongation of receptor signaling (Kimura
et al., 2012), and the promotion of cell proliferation.
EGFR signaling in tumor cells is regulated by the
competition between the galectin lattice and oligomerized
caveolin-1 microdomains for EGFR (Lajoie et al., 2007).
Morphological changes and cell detachment from the
matrix occur after receptor stimulation (Guo et al., 2007).
The cell detachment from the matrix is closely associated
with tumor cell migration (Wang et al., 2009; Pocheć et
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al., 2013). Results obtained from studies using knockout
GnT-V and antisense cell lines support this suggestion
(Seberger et al., 1999; Guo et al., 2001, 2007, 2010).
Knockout of GnT-V by siRNA expression causes lowered
expression of β1-6 branches on EGFR N-glycans without
any effect on EGFR expression level (Guo et al., 2007). The
EGFR signaling pathway maintains a balance among cell
proliferation, differentiation, and apoptosis and thus plays
an important role in the development and progression
of several human carcinomas (Al Moustafa et al., 2012).
Since occurrence of the epithelial-mesenchymal transition
phenotype is initiated via EGFR signaling (Huang et
al., 2013), downregulation of GnT-V has particular
importance.
3.2. Adhesion and signal molecules
The modification of N-linked glycans on adhesion
molecules such as E-cadherin and integrins can change their
functions (Pinho et al., 2011). Overexpression of GnT-V
provides the formation of β1-6 branches that bear a polyLacNAc extension. This branch is the cause of E-cadherinmediated tumor invasion (Pinho et al., 2013). Similarly,
increased expression on β1-6 branching on N-glycans of
β1-integrin inhibits the formation of fibronectin receptor
α5β1. This deficiency causes a decrease in ECM adhesion
and an increase in cell motility (Siddique et al., 2005). In
the case of a decrease in GnT-V activity, an enhancement of
integrin α5β1-dependent vascular endothelium adhesion
and subsequent transmigration occur (Yang et al., 2012).
These results indicate that N-glycan modification of the
adhesion and signal molecules has an important function
for migration and invasion activities of tumor cells.
3.3. Tumor-associated antigen (CD147)
CD147, a tumor-associated antigen, is a transmembrane
protein and a member of the immunoglobulin receptor
family and is highly expressed on the cell surface of
various tumor cells (Bai et al., 2014). The role of CD147
in tumorigenesis is related to the inducement of MMP
expression. It stimulates the secretion of MMPs from
fibroblasts to degrade the basement membrane and the
ECM, to facilitate cancer cell penetration, migration,
metastasis, and angiogenesis (Weidle et al., 2010; Chen
et al., 2012; Huang et al., 2013; Zhao et al., 2013). The
degradation of the ECM and the cell adhesion contacts, and
the formation of blood vessels, are the main events during
metastasis that are initiated with CD147. The stimulating
effect of CD147 on the production of MMPs reaches
the target cells by the vesicles. CD147 is released by an
extracellular vesicle shedding mechanism and transported
within the vesicle membrane. Although vesicle shedding
is common in normal cells, it occurs at much higher rates
in tumor cells (Redzic et al., 2013). Thus, the activation of
MMPs is triggered by GnT-V via CD147 (Lee et al., 2013).
Released CD147 contributes to the cells undergoing an

epithelial-to-mesenchymal transition by activating local
MMPs (Siu et al., 2013).
Overexpression of GnT-V results from the increase of
both CD147 and MMPs. CD147 contains high mannose and
complex type N-glycans bearing poly-LacNAc extensions
on β1-6 branches of the core structure. Heterogeneous
glycosylation of CD147 causes remarkable variations
in its size. According to the results from site-mutated
glycosylation studies, N-glycans of CD147 contribute to its
MMP-inducing activity and the most highly glycosylated
form of CD147 is more effective. Because β1-6 branched
glycans are high-affinity ligands for Gal-3, extracellular
Gal-3 triggers the clustering of membrane glycoproteins
that contain poly-LacNAc extensions. Gal-3 interacting
with poly-LacNAc on the CD147 and integrin β1 of retinal
pigment epithelial cells is responsible for modified cell
behavior (Priglinger et al., 2013). Aberrant β1-6 branching
glycans on CD147 probably play an important role in the
biological activity of CD147 (Zheng et al., 2006), which
has been considered as a potential tumor marker (Chen et
al., 2012; Huang et al., 2013).
3.4. Tissue inhibitor metalloproteinase-1 (TIMP-1)
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is also a
target protein for GnT-V.
TIMP-1 regulates the activity of MMPs (Groblewska
et al., 2012) and serves as a biomarker in gastric cancer
(Grunnet et al., 2013). Polylactosamination on the
β1-6 GlcNA branch and sialylation on TIMP-1 are both
characteristic in human colon cancer cells, WiDr, in
which GnT-V was overexpressed (Kim et al., 2008).
Glycosylation of TIMP-1 participates in the regulation
of interaction between MMPs (Kim et al., 2012). The
aberrant glycosylation of TIMP-1 is closely correlated with
invasive and metastatic potentials of colon cancer cells
by producing a weaker inhibition of MMPs, both in vivo
and in vitro. Thus, the function of TIMP-1 is associated
with the inhibition of MMPs, thereby blocking tumor
cell migration and invasion. However, independent of
their inhibitory activity on MMPs, TIMPs also have
direct cellular functions in normal tissue physiology
and disease progression. A novel therapeutic approach
to cancer treatment, involving the normalization of
the tumor microenvironment including normal ECM
components, was postulated (Stetler-Stevenson and Gavil,
2014). Involving the ability of TIMP-1 to act as a signaling
molecule with cytokine-like activities (Ries, 2014) support
this idea.
3.5. Membrane-bound serine protease (matriptase)
The other target protein for GnT-V is a type II
transmembrane serine protease, matriptase, alternatively
known as membrane-type serine protease-1 (MTSP-1).
Expression of matriptase in a variety of normal tissues
and especially in epithelial tissues (Takeuchi et al.,

763

KARAÇALI et al. / Turk J Biol

2000) suggests that this protease could regulate different
biological events (Ihara et al., 2004). The function of
matriptase is associated with epithelial homeostasis in
both health and disease situations (Gray et al., 2014).
Matriptase participates in tumor growth and progression
through the activation of 2 important cancer invasion
effectors, hepatocyte growth factor (HGF) and urokinase
plasminogen activator (uPA), on the surface of cancer
cells (Qiu et al., 2007; Kotthaus et al., 2010; Owen et al.,
2010). These proteins are involved in growth and motility
of cancer cells, particularly carcinomas, and in the
vascularization of tumors (Benaud et al., 2002). Proteases
mediate the degradation of ECM and intercellular adhesive
structures to allow penetration and migration of the
cells into the extracellular angiogenic factors. Matriptase
contributes to these processes (Uhland, 2006). Although
proteolytic activity in the close environment of the cells is
essential for tissue homeostasis, development, and repair,
the incorrect regulation of proteolysis can cause malignant
transformation (List et al., 2006; Bugge et al., 2007;
List, 2009). Matriptase positively regulates carcinoma
metastasis by activating the single-chain latent forms
of uPA and HGF and converting them into biologically
active forms (Suzuki et al., 2004; Kilpatrick et al., 2006;

Qiu et al., 2007; Lee et al., 2010). A direct relationship
between matriptase and GnT-V appears in human cancer
tissues (Ihara et al., 2004; Ito et al., 2006). Matriptase with
β1-6 GlcNAc catalyzed by GnT-V becomes resistant to
autodegradation and trypsin digestion. N-glycosidase
F-treated matriptase shows a greatly reduced resistance to
degradation. The active matriptase is rapidly inactivated
by hepatocyte growth factor activator inhibitor-1 (Chu et
al., 2014).
All these alterations occurring in the N-glycan common
core structure of cancer-associated proteins cause changes
in their molecular interactions and functions.
4. Conclusion
Markedly extensive efforts have been made to understand
the biological significance of protein glycosylation in cancer
in recent years. In cancer progression and metastasis, the
enzymes responsible for branching of the core structure
and in formation and extension of poly-LacNAcs play
very important roles. Elucidation of the interactions
between their molecular structures and the functions of
the associated enzymes, which are also glycoproteins, will
make important contributions to a better understanding of
tumor formation, progression, metastasis, and retardation.
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